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Cancer-associated fibroblasts promote bone
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Background: The molecular mechanisms involved in the invasion of bone by oral squamous cell carcinomas (OSCC) are poorly
understood, and little is known about the role of cancer-associated fibroblasts (CAF), the presence of which confers a poor
prognosis.
Methods: Clinicopathological data from 277 OSCC cases involving bone resections were reviewed, and 32 cases thoroughly
analysed histologically. Immunohistochemistry was used to examine aSMA, RANKL and OPG. Western blotting and qPCR were
used to assess myofibroblast (CAF-like) differentiation, RANKL and OPG expression in vitro, and RANKL secretion was analysed by
ELISA. Osteoclastogenesis was examined using TRAP staining, multinucleation and pit forming assays.
Results: Fibrous stroma intervened between tumour and bone in the majority of cases, with no direct contact between cancer cells
and bone. RANKL and OPG, two proteins key to regulating bone resorption, were expressed in tumour cells as well as fibrous
stroma adjacent to bone and aSMA-positive myofibroblastic CAF were consistently seen infiltrating into bone ahead of tumour
cells. Human primary osteoblasts cultured with conditioned media from human OSCC-derived cells and human primary CAF
showed a significant increase in RANKL and a decline in OPG mRNA expression. RANKL secretion was significantly increased in
primary oral fibroblasts induced to differentiate into a CAF-like phenotype by transforming growth factor-b1 (TGF-b1) treatment
and in primary CAF. Indirect co-culture of murine macrophages with conditioned media from CAF (experimentally derived and
isolated from OSCCs) resulted in a marked increase in osteoclastogenesis (in excess of that provoked by cancer cells) determined
by tartrate-resistant acid phosphatase activity, multinucleation and resorption pit formation.
Conclusions: This study is the first to describe a functional role for CAFs in bone invasion and turnover, identifying a novel
potential therapeutic target and diagnostic indicator in this difficult to treat bone invasive malignancy.
Oral squamous cell carcinoma (OSCC) is characterised by
heterogeneous morphological features and invasion of regional
anatomical structures. As the tumour grows it invades the
surrounding tissues and can penetrate proximal bone. The presence
of bone invasion worsens prognosis and upgrades the tumour stage,
with 12–56% of OSCCs presenting with bone invasion (Chen et al,
2011). The mechanism by which OSCC invades underlying bone
remains unclear, hampering prognosis and the development of
improved treatment strategies (Quan et al, 2012).
Recently it has become increasingly evident that the tumour
associated stroma (predominantly fibroblasts, endothelial cells,
inflammatory cells and associated matrix) plays a significant role in
tumour progression in OSCC (De Wever et al, 2008). Stromal
fibroblasts (cancer-associated fibroblasts, CAF) expressing the
myofibroblast marker a-smooth muscle actin (aSMA) have been
reported in several solid tumours, including OSCC, and their
presence is strongly associated with a poor clinical outcome
(Radisky et al, 2007). Ishikuro et al, 2008 demonstrated expression
of the osteoclastogenic factors RANK (receptor activator of nuclear
factor-kappaB) and its ligand RANKL in OSCC stroma adjacent to
bone but the precise role of stromal fibroblasts/CAF in bone
invasion remains unknown.
In the present study, we undertook a comprehensive clinical,
histopathological, and in vitro approach to analyse the contribution
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of stromal fibroblasts to bone invasive OSCC, and demonstrate for
the first time that CAFs promote osteoclastogenesis and are
intimately associated with tumour invasion into bone. These
findings suggest that interventions targeting the tumour stroma
may have promise as a novel therapeutic approach in bone invasive
OSCC.
MATERIALS AND METHODS
Case selection. Data from 277 OSCC cases with bone resection
was retrieved from the unit archive (1994–2014) and thoroughly
reviewed. The assessed criteria included those laid out in the
Royal College of Pathologists (RCPath) minimum data set such as
site of primary tumour, grade of tumour (well, moderate and
poorly differentiated), pattern of invasive front (cohesive and
discohesive), presence or absence of bone invasion, depth of
bone invasion (cortical or cancellous), lymph node metastasis,
lymphovascular invasion and perineural infiltration
(Supplementary Table S1).
Histological analysis. Paraffin-embedded sections (4 mm) were
obtained from 37 samples including 32 OSCCs with bone invasion
and five bone invasive ameloblastomas (locally aggressive odonto-
genic epithelial tumour with direct infiltration into bone) for
comparison. These cases were selected as being representative of
the entire cohort, with both maxillary and mandibular cases, as
well as cases showing cortical and cancellous invasion, included,
and with sufficient interface tissue available for analysis
and immunohistochemistry. Haematoxylin and eosin (H&E) and
martius scarlet blue (MSB) staining were carried out and
histologically evaluated (Supplementary Table S2). Depth of
tumour invasion in relation to underlying bone was examined
and characterised as cortical/superficial or cancellous/deep bone
marrow infiltration. Grade of OSCCs was assessed based on
Broder’s classification, and the tumours were graded as well,
moderate or poorly differentiated (Roland et al, 1992). The pattern
of tumour advancement was classified as cohesive or discohesive
using the recommended guidelines (Mu¨ller and Slootweg, 1990).
Host response was determined as strong, moderate or poor
(abundance of lymphocytic infiltration) in the tumour micro-
environment at the site of bone invasion (Supplementary Table
S2). Tumour and bone interface was also inspected for presence or
absence of fibroblastic stroma (loose myxoid-like appearance
comprising scanty collagen, and fibroblasts with fusiform nuclei).
The number of osteoclasts (large multinucleated cells in bone
lacunae, detected in three random high-power magnification
fields  40) at tumour-bone interface was also quantified
(Supplementary Table S3).
Immunohistochemical analyses. Immunohistochemistry was car-
ried out on matched cases of cortical (n¼ 5), cancellous (n¼ 5)
bone invasive OSCC resections and amelobastoma/control cases
(n¼ 5) (total¼ 15 cases). Immunohistochemistry for OPG,
RANKL and aSMA was performed as previously described
(Khurram et al, 2010) using the avidin-biotin peroxidase complex
(ABC) method (ethical approval 07/H1309/150). Tissue sections
were deparaffinised in xylene (10min), and rehydrated in absolute
alcohol (10min). Sections were incubated with 3% (v/v) hydrogen
peroxide in methanol (20min) to eliminate endogenous peroxidase
activity, and subsequently briefly rinsed in phosphate-buffered
saline (PBS). Heat-induced epitope retrieval was conducted for all
antibodies by microwaving in 0.01M tri-sodium citrate buffer (pH
6) for 5min, and cooled for 3min to avoid detachment of bone
tissue. After washing with PBS, blocking serum (100% horse serum
for mouse antibodies, and 100% goat serum for rabbit antibody)
was applied to sections for 30min at room temperature (RT).
Tissue sections were incubated with rabbit anti-human RANKL
polyclonal antibody (anti-RANKL antibody ab9957; abcam, Cam-
bridge, UK; 1:50), rabbit anti-human OPG polyclonal antibody
(anti-osteoprotegrin antibody ab73400; abcam; 1:100) diluted in
100% goat serum, mouse anti-human aSMA monoclonal antibody
(monoclonal anti-actin, a-smooth muscle antibody A5228; Sigma-
Aldrich, Poole, UK, 1:200) diluted in 100% horse serum, overnight
at 4 1C in a humidified chamber. Unbound primary antibody was
removed by washing in PBS followed by addition of secondary
biotinylated antibodies at RT for 30min in accordance with the
manufacturer’s instructions (Vectastain Elite ABC Kits, Vector
Laboratories, Burlingame, CA, USA). ABC solution was applied for
30min at RT and the slides washed in PBS. Nova Red Peroxidise
substrate kit (Vector Laboratories) was used as a chromogen,
sections were counterstained with Harris’s haematoxylin (Thermo
Electron Corporation, Loughborough, UK) and mounted in DPX.
Staining intensity/percentage was quantified in five random fields
per section at the tumour-bone interface using an Automated
Cellular Imaging System (ACIS III, Agilent, Santa Clara, CA,
USA).
Cell culture. Human primary osteoblasts HOB (passage 2) were
kindly provided by Dr Keyvan Moharamzadeh (Sheffield Research
Ethics Committee Ref. 15/LO/0116, STH18551). The OSCC-
derived cell line H357 was obtained from ATCC (Manassas, VA,
USA), and primary human oral fibroblasts (passage 7–8) were
isolated as previously described (Hearnden et al, 2009). Human
primary CAFs were isolated from fresh tissue derived from patients
with OSCC undergoing resections within the hospital (Sheffield
Research Ethics Committee Ref. 13/NS/0120, STH17021; CAF 002,
003 and 004, kindly provided by Amy Harding and Dr Helen
Colley), (Kabir et al, 2016). The murine macrophage cell line
(RAW 264.7) was acquired from ATCC (ATCC, TIB-71), and used
at passage 6.
HOB and H357 cell lines were cultured and maintained in
DMEM containing 10% (v/v) foetal calf serum, penicillin/
streptomycin (100 i.u.ml and 100 mgml 1, respectively), 2mM L-
glutamine, and fungizone (250mgml 1), while primary normal
fibroblasts and CAF were maintained in DMEM containing 10%
(v/v) foetal calf serum and 2mM L-glutamine. RAW 264.7 cells
were cultured in DMEM supplemented with 10% (v/v) foetal calf
serum and penicillin/streptomycin (100 i.u.ml and 100 mgml 1).
All cells were grown in T75 cm2 flasks, maintained in a 99%
humidified incubator at 37 1C in 5% CO2, and cultured until
70–80% confluence.
Culture of osteoblasts with conditioned media of H357 or CAF
003 and 004 was performed by seeding osteoblasts (250 000–
500 000 cells) into six-well plates. Cells were allowed to adhere
overnight followed by serum starvation for 24 h. Osteoblasts were
incubated with conditioned media from H357 OSCC-derived
cancer cells, experimentally derived CAF or OSCC-derived CAF
for 24 h. Osteoblasts cultured with serum-free media served as a
negative control. Finally, cells were lysed and RNA extraction was
performed immediately.
Quantitative real-time PCR (qPCR). Total RNA was extracted
from cultured cells using RNeasy Mini Kit (Qiagen, Crawley, UK)
and reverse transcribed to complementary DNA (cDNA) using a
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Thermo Fisher, Loughborough, UK). Following reverse
transcription the samples were subjected to Taqman qPCR analysis
(7900HT Fast Real Time PCR System; Life Technologies, Thermo
Fisher, Loughborough, UK). The Taqman primers (Life Technol-
ogies) used for amplification were as follows: RANKL (TNFSF11,
part no. Hs00243522_m1), OPG (TNFRSF1, part
no.Hs00900358_m1). aSMA transcripts were detected by SYBR
green qPCR (Life Technologies) using the following primers:
aSMA Forward 50 GAAGAAGAGGACAGCACTG 30, aSMA
Reverse 50 TCCCATTCCCACCATCAC 30 U6 Forward 50
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CTCGCTTCGGCAGCACA 30, U6 Reverse 50 AACGTTCAC-
GAATTTGCGT 30 (Hinsley et al, 2012). Amplification was
normalised to U6 (SYBR green) and human B2M (Taqman; part
no. 4331182, Life Technologies) in all samples using the Livak
method (Livak and Schmittgen, 2001).
Myofibroblast differentiation. Primary normal human oral
fibroblasts (NOF) were seeded into six-well plates and serum
starved for 24 h. Recombinant human TGF-b1 (5 ngml 1; R&D
Systems, Minneapolis, MN, USA) was added to the cells in serum-
free media and cells and medium harvested after 72 h, as previously
described (Kabir et al, 2016). NOF cultured in serum-free media
served as a negative control. Conditioned media was collected and
stored at  20 1C in preparation for ELISA.
ELISA for RANKL. A sandwich technique was performed using a
DuoSet ELISA development kit (Catalogue number: DY626, R&D
Systems), according to the manufacturer’s instructions, to detect
and quantify RANKL in conditioned medium collected from
NOFs, experimentally derived CAF, and OSCC-derived CAFs.
Western blot for aSMA expression. Proteins were extracted from
TGF-b1-stimulated oral myofibroblasts with RIPA buffer (20mM
Tris-HCl (pH 7.5), 1mM EDTA, 50mM b-glycerophosphate,
150mM NaCl, 1mM Na3VO4, 1% NP-40, 25mM NaF) containing
protease and phosphatase inhibitors cocktail (Sigma-Aldrich). The
solubilised proteins were resolved using SDS-PAGE and trans-
ferred onto polyvinylidene fluoride membranes (ATTO, Tokyo,
Japan). Protein identification was performed by western
blotting using primary antibodies raised against aSMA (1/1000;
Sigma, A5228) and GAPDH (1/5000; Abcam ab185059), diluted
in TBS containing 5% dried milk and 3% BSA, followed by
secondary antibodies conjugated with horseradish peroxidase.
Immunoreactive bands were detected using enhanced chemilumi-
nescence reagents (GE Healthcare; Pittsburgh, PA, USA).
Osteoclastogenesis assays. Macrophage (RAW 264.7) cells
(50 000 cells per ml in MEM-Alpha medium (Sigma) were
transferred to 24-well Corning Osteo Assay plates (catalogue
number- 3988, Corning). Conditioned media from serum starved
OSCC cells (H357), CAF, NOF or experimentally derived CAF was
collected, filtered using 0.22 mm Millex GP filter unit (Merck
Millipore Ltd, IRL, Feltham, UK), and added to the wells. Medium
containing recombinant RANKL (rRANKL, 50 ngml 1; Sigma)
served as a positive control. Serum-free differentiation media
served as a negative control. The plates were incubated in a 5%
CO2 humidified atmosphere at 37 1C for 7 days with a medium
change daily.
To verify osteoclast formation, tartrate-resistant acid phospha-
tase (TRAP) staining was performed using a TRAP staining kit
(B-Bridge International) according to the manufacturer’s instruc-
tions. Osteoclasts were identified by light microscopy as large
TRAP positive multinucleated (three or more nuclei) cells, and
quantified in three randomly selected high-power magnification
fields ( 40).
Separate wells of the 24 Osteo Assay plate were analysed for
osteoclast pit formation. Differentiation media was aspirated after
7 days, and 400 ml of 10% (v/v) sodium hypochlorite was added for
5min at RT. The wells were washed thoroughly with distilled water
and allowed to dry for 5 h. Pits and clusters were observed and
quantified using a light microscope (Nikon Eclipse TS-100,
Kingston-upon-Thames, UK) in three randomly selected high-
power magnification fields.
Fluoro cytochemical detection of multinucleated osteoclasts.
RAW 264.7 cells were seeded on coverslips in 24-well plates
(50 000 cells per well), and allowed to propagate in differentiation
media MEM-Alpha (Sigma) supplemented with 10% foetal calf
serum, 1% penicillin/streptomycin and 50 ngml 1 recombinant
RANKL (rRANKL; R-0525, Sigma), for 7 days, with a daily media
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Figure 1. Prevalent stromal presence in bone invasive OSCC. Photomicrographs of MSB and H&E stained bone invasive OSCC and
ameloblastoma tissue sections. (A) Abundant stroma in OSCC microenvironment, and extending into bone (H&E staining  10). (B) Fibrous tissue,
and thick collagen bundles surrounding ameloblastoma (H&E staining  10). (C) OSCC tumour islands and fibrous stroma invading bone,
osteoclasts evident in lacunae on bone resorptive surface (MSB staining  20). (D) Number of osteoclasts per high-power field proximal to OSCC
was significantly higher than ameloblastoma. Data represent the mean±s.d. (n¼3). ***Pp0.001.
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change. Media was removed, washed with PBS, followed by
formaldehyde (3.7% formaldehyde in PBS) fixation for 5min. Cells
were then dehydrated in acetone (5min), and permeabilised with 0.1%
Triton X-100 (Sigma) in PBS. After thorough washing in PBS, coverslips
were mounted on glass slides using SlowFade Diamond Antifade
Mountant containing DAPI (ThermoFisher) as a nuclear counterstain.
Images were obtained using a Axioplan 2 fluorescent microscope.
Statistical analysis. Data was expressed as mean± s.d.
Paired Student’s t-test and Fisher’s test was used to determine the
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Figure 2. Strong OPG and RANKL expression in OSCC tumour proximal to bone. Representative photomicrographs showing
immunohistochemical staining in bone invasive OSCC and ameloblastoma tissue sections. (A) Strong cytoplasmic OPG staining in osteoblasts in
bone resorptive regions in OSCC (magnification 10). (B) OPG staining in OSCC tumour islands, associated fibrous stroma and osteoclasts
(multinucleated cells) (magnification 10). (C) Strong RANKL (antibody dilution 1:50) staining in infiltrative tumour islands (magnification  20,
higher magnification of Figure 2B). (D) Pit forming osteoclasts (large cells with three or more nuclei) and surrounding tissue express RANKL on
bone resorptive surface (magnification  40). (E) OPG localisation in osteoblasts and weak expression in ameloblastoma stellate reticulum-like cells
(magnification 10). (F) Weak RANKL staining in ameloblastoma islands and osteoblasts (magnification  10). (G) Quantification of OPG and
RANKL staining intensity with significantly stronger RANKL staining in both cortical and cancellous bone invasive OSCCs compared to
ameloblastoma. No significant difference in OPG staining was detected. Data represents mean±s.d. **Pp0.01; ***Pp0.001; ****Pp0.0001.
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statistical significance of results where appropriate. A P-value of less
than 0.05 was considered statistically significant.
RESULTS
The presence of fibrous stroma is a prominent feature of bone
invasion. We first investigated the presence or absence of fibrous
stroma (indicative of the presence of CAFs) at the tumour-bone
interface in bone invasive OSCC (Figure 1A) and compared it to
ameloblastoma, a benign tumour of the odontogenic epithelium
which frequently infiltrates bone (Figure 1B). An estimated
90.62% (n¼ 29/32) of bone invasive OSCCs presented with
identifiable fibrous stroma, compared to only 20% (n¼ 1/5) of
ameloblastomas (Figure 1C and Supplementary Table S3). A
significantly higher number of osteoclasts were observed at the
bone interface in OSCC compared to ameloblastoma (Po0.001)
(Figure 1D).
Bone turnover markers are expressed in bone and stromal cells
at the tumour-bone interface. Expression of markers associated
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Figure 3. aSMA-positive stromal expression of OPG and RANKL between tumour and bone interface. Representative photomicrographs showing
immunohistochemical staining in stroma of bone invasive OSCC and ameloblastoma tissue sections. (A&B) OPG and RANKL expression detected
in osteoclasts (large multinucleated cells) on bone surface, and intervening fibroblasts. (C) Quantification of intensity of OPG and RANKL staining.
Data represent the means±s.d. (D) Strong aSMA-positive myofibroblastic stroma at advancing OSCC tumour front invading bone (magnification
 10). (E) Weak aSMA expression of blood vessels in ameloblastoma (magnification 20). (F) Quantification of intensity of aSMA expression
showed significantly stronger stromal staining in both cortical, and cancellous bone invasive OSCC, compared to ameloblastoma. Data represent
the means±s.d. *Pp0.05; **Pp0.01; ***Pp0.001; ****Pp0.0001.
CAF promote bone invasion in OSCC BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.239 5
with bone remodelling was analysed using IHC in selected matched
cases (n¼ 15). Cytoplasmic staining of OPG and RANKL was
evident in osteoblasts and osteoclasts as well as tumour cells
proximal to bone (Figure 2A–D). Interestingly, the staining intensity
appeared to gradually weaken in OSCC cells further away from bone
(Figure 2A–D). In ameloblastomas, weak OPG and RANKL
immunoreactivity was seen in the inner stellate reticulum-like cells
only (Figure 2E and F). RANKL staining was significantly stronger in
both cancellous and cortical OSCC bone invasion (Po0.001 and
Po0.00001 respectively) than ameloblastoma, while levels of OPG
immunoreactivity were similar (Figure 2G).
Both OPG and RANKL staining was also consistently observed
in fibrous stroma between tumour and bone, and particularly
surrounding osteoclasts in active bone resorptive sites (Figure 3A
and B). Although the intensity of expression varied between the
OSCC cases, only weak staining was observed in ameloblastomas
(data not shown). Stromal staining for RANKL and OPG
expression was significantly stronger in OSCC exhibiting either
cortical or cancellous bone invasion (Po0.01) than ameloblastoma
(Figure 3C).
Strong aSMA immunoreactivity was seen in fibrous stroma at
the tumour and bone interface, and surrounding osteoclasts, in
bone resorptive areas (Figure 3D), indicative of the presence of
CAF. Moreover, in several cases, aSMA-positive CAF were
observed infiltrating bone ahead of the epithelial tumour cells
(Figure 3D). Stromal aSMA staining proximal to bone was
significantly stronger in OSCC than ameloblastoma (Po0.002
cortical and Po0.00005 cancellous) (Figure 3E and F).
Human OSCC cells and CAFs enhance RANKL expression and
reduce OPG mRNA in human primary osteoblasts. Bone
remodelling depends upon a tightly regulated balance between
osteoblast-mediated bone deposition and osteoclastic bone resorp-
tion. Osteoclastic effects of RANKL are constrained by the
presence of its decoy receptor, OPG, both of which are secreted
by osteoblasts. To investigate the effect of OSCC-cell-derived
factors on OPG and RANKL expression in osteoblasts, HOB
primary human osteoblasts were cultured in H357 (an OSCC-cell
line)-derived conditioned media for 24 h. RANKL mRNA was
significantly upregulated in osteoblasts (Po0.001), with a
significant reduction in OPG mRNA compared to negative
controls (Po0.0001) (Figure 4A). Next, conditioned media
collected from primary CAFs was used to treat HOB osteoblasts.
A significant increase in RANKL mRNA (Po0.03) could be seen
in osteoblasts after 48 h (Figure 4A).
TGF-b1 stimulates RANKL expression in primary fibroblasts.
We next sought to determine if experimentally derived myofibro-
blastic CAF secrete RANKL. Previous work in our laboratory has
indicated that treatment of normal primary oral fibroblasts with
TGF-b1 provokes differentiation to a CAF-like, aSMA-positive
phenotype (Melling et al, in submission). Primary oral fibroblasts
were, therefore, treated with human recombinant TGF-b1
(5 ngml 1) for 72 h and differentiation to a CAF-like myofibro-
blastic phenotype was determined by examining the expression of
aSMA protein, which increased significantly in response to TGF-
b1 treatment (Figure 4B). Conditioned media was collected from
control fibroblasts and TGF-b1-treated CAF-like fibroblasts and
RANKL secretion examined by ELISA. TGF-b1 treatment resulted
in a significant upregulation of RANKL in the conditioned media
(Figure 4C, Po0.05). Conditioned media from serum starved
OSCC-derived CAF (three separate cultures) were collected and
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Figure 4. CAFs stimulate expression of RANKL in osteoblasts. (A) mRNA expression of OPG and RANKL in human osteoblasts (HOB) following
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compared to media gathered from NOFs (three separate cultures)
under identical conditions. RANKL secretion was quantified by
ELISA and a significant increase in RANKL expression noted in
CAF- compared to NOF-derived media (Figure 4D).
CAF directly promote osteoclastogenesis. Given the ability of
experimentally derived CAF to generate and secrete RANKL (and
other osteoclastogenic factors such as IL-6 and MCP-1 (Kabir et al,
2016)), we next sought to examine the effect of CAF-derived
conditioned medium on osteoclastogenesis. Both experimentally
derived CAF and primary CAF-derived from OSCC, as well as
OSCC-derived cancer cells, were able to induce tartrate-resistant
acid phosphatase (TRAP) (Figure 5A and B) pit formation in a
synthetic bone substrate and multinucleation of macrophages
(Figure 5A and C) at a significantly higher level than normal
fibroblasts. Surprisingly, the effect of CAF on osteoclastogenesis was
markedly greater than OSCC-derived cancer cells (Figure 5A–C).
DISCUSSION
OSCC has a high tendency to invade proximal bone, a feature
conferring significant morbidity and a poor prognosis (Nomura
et al, 2005). In this study, we aimed to examine the extent to which
the tumour microenvironment, and in particular CAF, influence
bone invasion. The presence of prominent stroma in bone invasive
OSCC has previously been reported, but these were largely
observational studies lacking robust experimental interrogation of
functional CAF or clinicopathological correlation (Wong et al,
2000; Ebrahimi et al, 2011; Fried et al, 2014). We sought to
examine the association between stroma and bone invasion in
more detail and have identified for the first time a prominent
functional role for CAF in bone invasive OSCC.
A discohesive invasion pattern for OSCC is known to be
associated with a more destructive behaviour (Totsuka et al, 1991;
Ishikuro et al, 2008; Ebrahimi et al, 2011). This was consistent with
our observation that the advancing tumour front, when in close
proximity to or invading bone tissue, was of a discohesive nature.
In addition, osteoclast count in OSCC was significantly higher than
ameloblastoma, suggesting higher bone turnover and resorption in
OSCC similar to previous findings (Ishikuro et al, 2008).
Interestingly, in the majority of cases analysed in our cohort, no
direct contact between tumour and bone was evident, with
abundant fibrous and variably desmoplastic stroma present at
the OSCC tumour-bone interface. This contrasted with amelo-
blastoma, in which thick bundles of hyalinised collagen were
present between tumour islands and bone with minimal aSMA
staining.
A strong correlation between the presence of aSMA-positive
stromal CAFs and poor patient outcome has been reported in a
range of malignancies including breast (Surowiak et al, 2007),
colorectal (Tsujino et al, 2007) and oesophageal (Saadi et al, 2010)
carcinomas, as well as OSCC (Vered et al, 2010; Marsh et al, 2011).
In our study, strong aSMA expression was seen in fibrous stroma
of all bone invasive OSCC samples. In numerous cases, aSMA
fibroblasts were noted visibly infiltrating bone, ahead of the
epithelial tumour component, strongly supporting our hypotheses
that a myofibroblastic stroma plays a crucial role in bone invasive
OSCC. In contrast, ameloblastoma, a benign/locally invasive
odontogenic tumour, only showed sporadic and weak aSMA
staining in fibroblasts.
It has been suggested that the disequilibrium in osteolytic
RANKL and OPG expression enhances progression of bone-
associated malignancies (Jimi et al, 2013). We have shown that in
addition to bone cells, tumour cells and fibrous stroma, as well as
CAF in culture, express RANKL and OPG. Although some studies
have shown RANKL expression in tumour cells in close proximity
to bone (Ishikuro et al, 2008; Chaung et al, 2009; Kayamori et al,
2010), reports of OPG expression are variable and the absence of
expression has also been reported in one study (Ishikuro et al,
2008). However, a recent study has reported OPG upregulation in
bone invasive OSCC (Russmueller et al, 2015) suggesting that
enhanced OPG expression depletes TNF-related apoptosis-indu-
cing ligand (TRAIL) -induced cell apoptosis, hence promoting
survival of tumour cells, which may explain the readily detectable
levels of OPG in the stroma observed here.
Osteoblasts cultured with conditioned media from OSCC cells
showed elevated RANKL expression and reduced OPG levels, in
agreement with previous reports showing RANKL mRNA
amplification and OPG reduction in BHY murine osteoblasts
cultured with OSCC-conditioned media (Ishikuro et al, 2008). Our
findings also show for the first time that OSCC-derived CAF and
experimentally derived CAF-like fibroblasts are able to invoke
similar responses in osteoblasts, suggesting that CAF may play a
functional role in bone remodelling in OSCC.
Bone destruction and OSCC invasion requires the generation of
osteoclasts (multinucleated bone resorbing cells) originating from
monocyte/macrophage lineage haematopoietic precursors. It has
been previously reported that exposure to RANKL facilitates
osteoclastogenesis in the murine macrophage cell line RAW 264.7
(Vincent et al, 2009), and a similar effect is seen in response to
cancer-cell-derived factors. This was corroborated by our findings
obtained with OSCC-cell-derived conditioned media. Interestingly,
we also observed a significantly greater stimulation of osteoclas-
togenesis following incubation of RAW 264.7 cells in conditioned
media from CAF (OSCC-derived and experimentally derived) with
morphological transdifferentiation after 5 days, TRAP positivity
within 7 days and pit formation on osteo-surface wells (Halleen
et al, 2000).
In conclusion, our data provide, for the first time, ex vivo and
in vitro evidence that CAF have a key role in bone invasion in
OSCC manipulated through a RANKL-dependent pathway. This
suggests that stromal factors may hold promise as novel
therapeutic targets in bone invasive OSCC.
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